Trial Profile
A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary) ; Trastuzumab emtansine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 28 Feb 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Feb 2019 Planned End Date changed from 1 Feb 2021 to 15 Jun 2021.
- 04 Feb 2019 Planned primary completion date changed from 1 Feb 2020 to 15 Jan 2021.